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INTRODUCTION AND OBJECTIVES
Mesenchymal stem cells (MSCs) are nonhematopoietic multipotent stem cells shown for the first time in bone marrow, but they have also been isolated from 
other sources. Particularly, MSCs derived from bone marrow (BM-MSCs) and adipose tissue (AD-MSCs) are the most highly characterized and are considered 
comparable. Both have demonstrated broad multipotency with differentiation in adipocytic, osteocytic and chondrocytic cell lineages. However, the easy and 
repeatable access to adipose tissue, the simple isolation procedure and the greater numbers of fresh MSCs derived from equivalent amounts of fat versus bone 
marrow provide a clear advantage in using AD-MSCs over BM-MSCs. 
This study compared some characteristics of canine AD-MSCs from subcutaneous and visceral fat. These findings were directed to obtain high quantity and 
quality AD-MSCs for clinical cell-based therapy.
RESULTS AND CONCLUSION
The isolated AD-MSCs adopted a fibroblast-like shape (Figure 6). Statistical analysis demonstrated that subcutaneous and visceral fat yielded the same number 
of cells/g of fat. We also demonstrated that in a non-inductive medium the AD-MSCs reached the highest proliferative capacity, especially when derived from 
subcutaneous fat (Figure 7). Data shown that the obtained CFU number grew up to P2 and decreased in subsequent passages. 
Cells derived from subcutaneous fat gave higher mean values of CFU than those of cells deriving from visceral fat in all of six passages (Figure 8). AD-MSCs
differentiated in chondrocytes, adipocytes and osteocytes (Figures 3, 4, 5) up to P4. RT-PCR analysis revealed that cells expressed pluripotency-associated 
transcription factors Oct4, Nanog and Sox2 up to P6, but the mRNA expression level was higher at P2.
Finally, the results of our study showed that the AD-MSC from subcutaneous fat, grown up to P2 in our culture condition, were most suitable to use in 
regenerative therapy.
MATERIAL AND METHODS
Subcutaneous and visceral fat samples were 
collected (Figure 1) from 2 different groups of 
10 healthy donor dogs. The AD-MSCs were 
isolated from each sample and were cultured in 
Dulbecco’s modified Eagle’s medium-Low 
Glucose with 20% Fetal Bovine Serum. 
Cell yield (number of cells/g of fat) was 
evaluated. AD-MSCs were sub-cultured up to 
passage (P) 6 and their proliferation potential 
was evaluated. The identity of AD-MSCs of each 
passage was verified by their ability to attach to 
flasks surface, to produce colony-forming units 
(CFU) (Figure 2) and to differentiate in 
chondrocytes, adipocytes and osteocytes. 
The presence of transcription factors indicating 
self-renewal and undifferentiation (Oct4, Nanog
and Sox2) were also investigated by RT-PCR 
analysis.
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Fig. 2.  CFU 50X Fig. 3.  Alizarina Red Staining (Ca2+)
Fig.4.  Oil Red O Staining (lipids) Fig. 5. Chondrocyte nodule Fig.6. Fibroblast-like AD-MSCs
Fig. 1.  Sample collection
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Fig.6. Cumulative pd of AD-MSC derived from visceral and subcutaneous fat
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Fig. 7. CFU-F potential of AD-MSCs from canine visceral and subcutaneous fat
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